Also in BioCentury’s Clinical Report: CG’s oncolytic virus success, ivonescimab’s latest lung cancer win, and more

BioCentury’s roundup of translational innovation also includes a new target for arrhythmia and four papers with links to newcos

Company went from idea to clinical proof of concept for

The target is one of industry’s most notable case studies in continued product differentiation and market growth 

Plus: Neurocrine’s schizophrenia therapy, Medicxi-backed Vaderis’ treatment for rare vascular disorder both look to advance; plus a miss for Leo’s Timber